Null genotypes of glutathione S-transferase $\mu$1 and glutathione S-transferase $\theta$1 are associated with osteosarcoma risk: A meta-analysis

JICHENG HAN, WEI DENG, LAIYING WANG and WANLI QI

Department of Orthopaedics, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin 130000, P.R. China

Received March 26, 2014; Accepted December 16, 2014

DOI: 10.3892/ol.2015.2955

Abstract. Glutathione S-transferase (GST) genetic polymorphisms has been reported to be associated with osteosarcoma; however, the results of previous studies are conflicting. Thus, in the present study, a meta-analysis was conducted to investigate the effects of GSTM1 and GSTT1 polymorphisms on osteosarcoma risk. A literature search was performed in the PubMed, Cochrane Library and China National Knowledge Infrastructure databases to identify case-control studies published prior to March 2014. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. In addition, Begg's test was used to measure publication bias. Sensitivity analysis were performed to ensure the accuracy of the results. The meta-analysis results demonstrated no significant association between the null genotype of GSTM1 and osteosarcoma risk (OR=0.83; 95% CI, 0.37‑1.85). By contrast, the results revealed a significant association for the comparison of null vs. non-null genotypes of GSTT1 (OR=1.54; 95% CI, 1.09‑2.19). In conclusion, the GSTT1 null genotype may be associated with an increased risk of developing osteosarcoma. Further studies with larger sample sizes and well-designed methodologies are required to verify these conclusions.

Introduction

Osteosarcoma is a highly malignant and aggressive bone tumor, occurring primarily in individuals between 10 and 30 years old (1). This tumor accounts for ~45% of all the bone sarcomas. Although five-year survival rates of 50-70% can be achieved through multimodal therapy, the lack of effective treatment options results in poor prognosis in a large number of patients (2). Further investigation of the pathogenesis of osteosarcoma is required to reduce the morbidity and mortality rates. A previous study has demonstrated that the established risk factors involved in the development of osteosarcoma include the following: Adolescent and young adult age, male gender, previous treatment with radiotherapy or anticancer drugs, particularly alkylating agents, and a family history of osteosarcoma (1). However, the etiology of osteosarcoma is not fully understood based on these risk factors; therefore, additional risk factors may be involved (3). Molecular biology studies have revealed strong evidence that genetic factors are important in the pathogenesis of osteosarcoma (4,5).

Glutathione S-transferases (GSTs) are a family of phase II enzymes (6). GSTs are mainly responsible for the detoxification of a wide range of environmental and nonenvironmental carcinogens (including polyaromatic hydrocarbons from second-hand cigarette smoke), chemotherapy agents (including alkylating agents and anthracyclines), inflammation-associated reactive oxygen species and metabolism-derived lipid peroxides (7). In addition, GSTs are able to modulate the induction of other enzymes and proteins that are important for cellular functions (8). Thus, GSTs are involved in the protection against various types of cellular damage and their malfunction may result in carcinogenesis.

In humans, the GST super family consists of numerous cytosolic, mitochondrial and microsomal proteins. Cytosolic proteins are divided into eight distinct classes, including the $\alpha$, $\kappa$, $\mu$, $\omega$, $\pi$, $\sigma$, $\theta$ and $\zeta$ (9). The $\theta$ class of GSTs is encoded by the GST $\theta$1 (GSTT1) gene, which is located on chromosome 1p13.3 and contains 10 exons (10). In addition, the $\mu$ class is encoded by the GST $\mu$1 (GSTM1) gene on chromosome 22q11.23 and contains six exons (11). Homozygous deletion (null genotype) is the most common variant of the GSTM1 and GSTT1 genes. In the Caucasian European populations, the prevalence of the GSTM1 deletion genotype is 47-58%, while the prevalence of the GSTT1 null genotype is 13-25% (12). A previous study has indicated that the null genotype may be associated with the absence of enzyme activity, increasing vulnerability to cytogenetic damage and resulting in susceptibility to cancer (13).
A previous study revealed that the null genotypes of GSTT1 and GSTM1 were associated with increased risk of bladder and prostate cancer (14). In addition, a number of studies have investigated the association between GSTM1 and GSTT1 polymorphisms and the risk of developing osteosarcoma (15,17,18). However, the results of these studies were inconsistent. A meta-analysis can be useful in the detection of an association that may not be identified in sample size studies, particularly studies evaluating rare allele frequency polymorphisms. The aim of the present study was to investigate the association between the null genotypes of GSTM1 and GSTT1 and the development of osteosarcoma by conducting a meta-analysis investigation of all the eligible case-control studies published to date.

Materials and methods

Literature search. The literature was screened (titles, abstracts and full text) by two researchers independently, in order to determine which studies were eligible for inclusion in this meta-analysis. The results were compared and disagreements were resolved by consensus. The PubMed (www.ncbi.nlm.nih.gov/pubmed), Cochrane Library (www.thecochranelibrary.com) and China National Knowledge Infrastructure (http://www.cnki.net) databases were examined to identify all the studies investigating the association between GSTM1 and GSTT1 polymorphisms and osteosarcoma risk, which were published prior to March 2014. The following key words were used: ‘glutathione S-transferases’, ‘GST’, ‘osteosarcoma’, ‘polymorphism’, ‘mutation’ and ‘variant’. No publication language restrictions were imposed. The references of all the studies identified through the literature search were investigated for other relevant publications. In the case that sequential or multiple publications using the same data were identified, the publication reporting data from the largest or most recent study was included. The search strategy used in this study is shown in Table I.

Inclusion and exclusion criteria. The inclusion criteria for human studies included the following: i) Case-control studies, addressing osteosarcoma cases and healthy controls; ii) studies evaluating the association between GSTM1 and GSTT1 polymorphisms and osteosarcoma risk; and iii) studies that included sufficient genotype data for extraction. The exclusion criteria included the following: i) Non-case-control studies, evaluating the association between GSTM1 and GSTT1 polymorphisms and osteosarcoma risk; ii) case reports, letters, reviews, meta-analyses and editorial articles; iii) studies reporting incomplete or insufficient data; iv) studies containing duplicate data; and v) studies with a family-based design.

Data extraction. The data were independently examined and extracted by two researchers, based on the aforementioned inclusion and exclusion criteria. In the case of inconsistency between the studies selected by the two researchers, consensus was reached following discussion. The following information was collected from the eligible studies: First author's name; year of publication; country and ethnicity of the studied population; number of cases and controls; and number of genotyped cases and controls. The cases and controls were categorized into the Asian or Caucasian ethnic groups. No minimum number of patients was required to include a study in this meta-analysis.

Statistical analyses. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to determine the strength of association between the GSTM1 and GSTT1 polymorphisms and osteosarcoma risk. Pooled ORs for the risk associated with the GSTM1 and GSTT1 null genotypes vs. the non-null genotypes were calculated. Heterogeneities between the studies were estimated using the $I^2$ test. $I^2$ values of 25, 50 and 75% were defined as low, moderate and high estimates, respectively (15). When the $I^2$ value was >50%, indicating heterogeneity across the studies, the random effects model was used for meta-analysis; otherwise, the fixed effects model was used. In addition, subgroup analysis based on ethnicity was used to investigate and interpret the diversity among the results of different studies. Sensitivity analysis was performed by using random effect values compared with the fixed effect in order to ensure the stability of the findings (16). Publication bias was investigated using Begg’s funnel plot and $P<0.05$ was considered to indicate a statistically significant publication bias. All the analyses were performed using the STATA version 12.0 software (StataCorp LP, College Station, TX, USA) and the significance level was set to 0.05.

Results

Identification of eligible studies. Based on the search criteria used in the present study, 31 individual manuscripts were identified. Of these, eight full-text publications were preliminarily selected for further detailed evaluation. According to the exclusion criteria, five of these publications were then excluded, including one duplicate study, one meta-analysis and three studies with insufficient data for extraction. Finally, as shown in Fig. 1, three studies with 202 cases and 712 healthy controls were included in the current meta-analysis (17-19). A flow chart demonstrating the study selection process is summarized in Fig. 1. All the eligible studies were case-control studies that evaluated the association of the GSTM1 and GSTT1 null genotypes with the susceptibility to osteosarcoma. The publication year range of the included studies was between 2000 and 2014.

Figure 1. Flow chart of study study selection based on the inclusion and exclusion criteria.
Table I. Characteristics of literatures included in the meta-analysis.

| Study included | Year | Country | Ethnicity | Genotyping               | Cases/controls | Cases | Controls |
|----------------|------|---------|-----------|--------------------------|----------------|-------|----------|
|                |      |         |           |                          |                |       |          |
| GSTM1          |      |         |           |                          |                |       |          |
| Barnette et al | 2004 | America | Caucasian | High-throughout assay    | 12/326         | 6     |          |
| Carolina et al | 2010 | Brazil  | Caucasian | PCR-RFLP                 | 80/160         | 20    |          |
| Lu et al       | 2011 | China   | Asian     | TaqMan assay             | 110/226        | 40    |          |

| Study included | Year | Country | Ethnicity | Genotyping               | Cases/controls | Cases | Controls |
|----------------|------|---------|-----------|--------------------------|----------------|-------|----------|
|                |      |         |           |                          |                |       |          |
| GSTT1          |      |         |           |                          |                |       |          |
| Barnette et al | 2004 | America | Caucasian | High-throughout assay    | 12/300         | 2     |          |
| Carolina et al | 2010 | Brazil  | Caucasian | PCR-RFLP                 | 80/160         | 20    |          |
| Lu et al       | 2011 | China   | Asian     | TaqMan assay             | 110/226        | 40    |          |

GSTM1, glutathione S-transferase (GST) μ1; GSTT1, GST θ1; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism.

Figure 2. Meta-analysis of the association between the null genotype of glutathione S-transferase μ1 and osteosarcoma risk.

Figure 3. Meta-analysis of the association between the null genotype of glutathione S-transferase θ1 and osteosarcoma risk.
In total, three case-control studies were found to be eligible and assessed quantitatively the association between the GSTM1 and GSTT1 null genotypes and osteosarcoma risk. The current study meta-analysis of the association between GSTM1 and GSTT1 null genotypes and osteosarcoma. As important phase II enzymes, the GSTM1 and GSTT1 null genotypes are known to eliminate carcinogens (13). As important phase II enzymes, the GSTM1 and GSTT1 null genotypes are known to eliminate carcinogens (13). A recent study demonstrated that GSTT1 is exhibit phase I enzyme activity and possess the ability to activate carcinogens (17). The null genotype of GSTT1 is associated with the absence of enzyme activity and an increased cancer incidence. As the number of eligible studies selected in the present meta-analysis was small, these results require further verification. The limitations of the current meta-analysis should be acknowledged. Firstly, the systematic review was based on unadjusted data, since the genotype information stratified for the main confounding variables was not available in the original studies, while the confounding factors addressed across the different studies were variable. In addition, this meta-analysis was not able to address all the sources of heterogeneity that existed among the previous studies for the majority of polymorphisms, although subgroup stratification analysis may be possible for the limited number of the included published studies. Furthermore, gene-gene and gene-environment interactions were not investigated in the present study, due to the lack of information from the original studies.

In conclusion, the present meta-analysis indicated that the GSTT1 null genotype was associated with an increased risk of osteosarcoma and the risk of osteosarcoma (OR=0.83; 95% CI, 0.37-1.85). By contrast, the results demonstrated that the GSTT1 null genotype was significantly associated with the susceptibility to osteosarcoma (OR=1.54; 95% CI, 1.09-2.19). No evidence of publication bias was detected in this meta-analysis for the GSTM1 and GSTT1 null genotypes (P>0.05).

The underlying mechanism of the association between the GSTT1 null genotype and osteosarcoma risk remains unclear. A recent study demonstrated that GSTT1 is different compared with other phase II enzymes (such as GSTM1), which also exhibit phase I enzyme activity and possess the ability to activate carcinogens (17). The null genotype of GSTT1 is associated with the absence of enzyme activity and an increased cancer incidence. As the number of eligible studies selected in the present meta-analysis was small, these results require further verification.

The limitations of the current meta-analysis should be acknowledged. Firstly, the systematic review was based on unadjusted data, since the genotype information stratified for the main confounding variables was not available in the original studies, while the confounding factors addressed across the different studies were variable. In addition, this meta-analysis was not able to address all the sources of heterogeneity that existed among the previous studies for the majority of polymorphisms, although subgroup stratification analysis may be possible for the limited number of the included published studies. Furthermore, gene-gene and gene-environment interactions were not investigated in the present study, due to the lack of information from the original studies.

In conclusion, the present meta-analysis indicated that the GSTT1 null genotype was associated with an increased risk of developing osteosarcoma. Since only a small number of studies are available in this field and the current evidence remains limited, future studies with large sample groups and adequate methodological quality are required to obtain accurate results.

References

1. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543, 2009.
2. Walkley CR, Qudsi R, Sankaran VG, et al: Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 22: 1662-1676, 2008.
3. Both J, Krijgsman O, Bras J, et al: Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma. PLoS One 9: e115835, 2014.
4. Sadikovic B, Thorner P, Chilton-Macneill S, et al: Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 10: 202, 2010.
5. Gokgoz N, Wunder JS, Mousses S, et al: Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 92: 2181-2189, 2001.
6. Toh CK, Gao F, Lim WT, et al: Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 24: 2245-2251, 2006.
7. Krajnovic M, Labuda D, Richer C, Karimi S and Sinnett D: Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 93: 1496-1501, 1999.
8. Hayes JD, Flanagan JU and Jowsey IR: Glutathione transferases. Annu Rev Pharmacol Toxicol 45: 51-88, 2005.
9. Strange RC, Spiteri MA, Ramachandran S, and Fryer AA: Glutathione-S-transferase family of enzymes. Mutat Res 482: 21-26, 2001.
10. Webb G, Vaska V, Coggan M and Board P: Chromosomal localization of the gene for the human theta class glutathione transferase (GSTT1). Genomics 33: 121-123, 1996.
11. Pearson WR, Vorachek WR, Xu SJ, et al: Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet 53: 220-233, 1993.
12. Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6: 733-743, 1997.
13. Mellwain CC, Townsend DM, and Tew KD: Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25: 1639-1648, 2006.
14. Steinhoff C, Franke KH, Golka K, et al: Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol 74: 521-526, 2000.
15. Wu MS, Huang SP, Chang YT, et al: Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J Infect Dis 185: 106-109, 2002.
16. Wang YJ and Pan Y: The M235T polymorphism in the angiotensinogen gene and myocardial infarction risk: a meta-analysis. J Renin Angiotensin Aldosterone Syst 15: 294-300, 2014.
17. Barnette P, Scholl R, Blandford M, et al: High-throughput detection of glutathione s-transferase polymorphic alleles in a pediatric cancer population. Cancer Epidemiol Biomarkers Prev 13: 304-313, 2004.
18. Salinas-Souza C, Petrilli AS and de Toledo SR: Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenet Genomics 20: 507-515, 2010.
19. Lu XF, Yang WL, Wan ZH, et al: Glutathione S-transferase polymorphisms and bone tumor risk in China. Asian Pac J Cancer Prev 12: 3357-3360, 2011.
20. Salanti G, Sanderson S and Higgins JP: Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7: 13-20, 2005.